A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
This study is looking at new combination treatments for people with advanced non-small cell lung cancer that carries a specific genetic change called KRAS G12C. In many cancers, this faulty gene sends constant signals that cause cells to divide and grow out of control. Adagrasib is a targeted drug designed to switch off this faulty signal. In this phase 2 trial, doctors are combining adagrasib with well-known cancer treatments, including immunotherapy (pembrolizumab) and chemotherapy drugs (such as pemetrexed and carboplatin). The main goal is to find out whether these combinations are safe and how well they work to shrink tumours and delay the cancer from worsening. The study also measures how long any positive response lasts and checks for side effects to ensure the combinations are as safe as possible for patients.
At a glance
What is this study about?
Lung cancer is one of the most common cancers in the UK. Non-small cell lung cancer is the most frequent type. In recent years, doctors have discovered that some lung cancers are driven by specific changes in the cancer cells' DNA. One of these changes is known as the KRAS G12C mutation. When this mutation is present, it acts like a broken switch that is stuck in the 'on' position, telling cancer cells to multiply rapidly.
Adagrasib is a modern targeted therapy designed specifically to turn this broken switch off. While adagrasib can work on its own, researchers believe it might work even better when paired with other established cancer treatments. In this trial, participants receive adagrasib alongside standard treatments such as pembrolizumab (an immunotherapy that helps your immune system spot and destroy cancer cells) or chemotherapy (medicines that kill fast-growing cells).
Because this is a phase 2 trial, doctors are exploring how effective these new drug pairings are at shrinking tumours and keeping the cancer stable over several months. They will also carefully monitor safety, checking the type and severity of any side effects to make sure the benefits of the treatment outweigh the risks for patients.
Key takeaways
- Tests the targeted drug adagrasib combined with standard immunotherapy or chemotherapy.
- Aimed at adults with advanced non-small cell lung cancer carrying the KRAS G12C mutation.
- Phase 2 trial designed to check how well the drug combination shrinks tumours and how safe it is.
- Participation involves regular hospital visits, oral medication, intravenous drips, and regular imaging scans.
- Taking part is voluntary, and you can withdraw at any time.
Who may be eligible?
This trial is open to adults aged 18 and over who have been diagnosed with advanced non-small cell lung cancer. 'Advanced' means the cancer has spread within the chest or to other parts of the body, making it difficult to treat with surgery alone.
To be considered, your tumour must have tested positive for the KRAS G12C genetic mutation. Your cancer team can check this using a tissue sample taken during a previous biopsy or sometimes through a specialised blood test.
People taking part need to be well enough to carry out basic daily activities and have reasonably healthy liver, kidney, and bone marrow function. Your study doctor will review your full medical history and current medications to confirm whether the trial is safe and appropriate for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or older.
- I have been diagnosed with advanced non-small cell lung cancer.
- My cancer has tested positive for the KRAS G12C gene change (or I am willing to be tested).
- I am well enough to attend regular clinic appointments and manage daily self-care.
- I am willing to take oral tablets and receive medicines through a drip.
What does participation involve?
Taking part in this study means visiting the hospital regularly for treatment and health checks. Adagrasib is taken by mouth as tablets or capsules, while other treatments, such as chemotherapy or pembrolizumab, are given as an infusion through a drip into a vein. Before starting, and at regular points throughout the study, you will have CT or MRI scans to see how your tumour is responding. You will also have regular blood tests, physical checks, and heart traces (ECGs) to monitor your overall health. You will be asked to report any side effects you notice. Treatment continues as long as it is helping you and the side effects remain manageable, and your doctor will follow up with you after treatment finishes.
Potential risks and benefits
Locations (6)
- —UnverifiedHungary
- —UnverifiedPoland
- —UnverifiedSpain
- —UnverifiedFrance
- —UnverifiedItaly
- —UnverifiedGreece
Common questions
What is a KRAS G12C mutation?
It is a specific, faulty gene found inside some cancer cells. It acts like an accelerator pedal, causing the cancer cells to grow and spread.
How is adagrasib given?
Adagrasib is an oral medication, meaning it is taken by mouth as a pill, while the chemotherapy or immunotherapy drugs are given into a vein.
Will I receive a placebo (dummy treatment)?
No, this study is testing real combinations of active cancer medicines; no dummy treatments or placebos are used.
Do I have to pay to take part?
No. The trial medication and all study-related tests are provided free of charge, and some travel expenses may also be covered.
Can I stop taking part if I change my mind?
Yes. Taking part is completely voluntary, and you can leave the trial at any point without your standard NHS care being affected.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.